Fagron NV (FAGR.BR) — Quality & forensics
As of 2026-10-12 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 59
- Quality 54
- Growth 56
- Balance sheet 53
- Cash quality 39
- Capital allocation 52
- Momentum 42
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the grey zone (1.81–2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the FAGR.BR chart & overview
FAQ · from the current data · as of 2026-10-12
Quick answers
What is Fagron NV's Closelooknet quality reading?
The composite reads 52/100 across 7 modules, as of 2026-10-12: valuation 59, quality 54, growth 56, balance sheet 53, cash quality 39, capital allocation 52, momentum 42. Closelooknet scores are research diary readings, not ratings or investment advice.
What is Fagron NV's Altman Z-Score?
2.80, which sits in the grey zone (1.81–2.99) as of 2026-10-12. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Fagron NV's Piotroski F-Score?
5 of 9, as of 2026-10-12. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Fagron NV's Beneish M-Score indicate?
-1.90 — below the −1.78 manipulation-risk threshold, as of 2026-10-12. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- ROVI.MC Laboratorios Farmaceuticos ROVIindustry
- LNTH Lantheus Holdings Incindustry
- KNSA Kiniksa Pharmaceuticals Ltdindustry
- BHC.TO Bausch Health Companies Incindustry
- GALDY GALDERMA GROUP AGindustry
- ALKS Alkermes Plcindustry
- PRGO Perrigo Company PLCindustry
- HCM.L HUTCHMED China Ltdindustry
- AMRX Amneal Pharmaceuticals, Inc. Class A Common Stockindustry
- UTHR United Therapeutics Corporationindustry
- VTRS Viatris Incindustry
- ZTS Zoetis Incindustry
- DMP.DE Dermapharm Holding SEindustry
- ELAN Elanco Animal Healthindustry
- ALM.MC Almirall S.A.industry
- NBIX Neurocrine Biosciences Incindustry
- APTX.TO Apotex Health Corpindustry
- ARGX.BR Argen-Xsector
- UCB.BR UCB SAsector
- TUB.BR Tubize-Finsector